Myla Strawderman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Myla Strawderman has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Adnin Zaman
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
3 shared publications - Susan W. Groth
School of Nursing, University of Rochester, Rochester, NY 14642, USA
3 shared publications - Aaron Lazorwitz
Division of Complex Family Planning, Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University, New Haven, CT 06510, USA
2 shared publications - Ajay Dhakal
Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA
2 shared publications - Barbara Lohse
Wegmans School of Health and Nutrition, Rochester Institute of Technology, Rochester, NY 14623, USA
2 shared publications Nimish Mohile
Division of Neuro-Oncology, Department of Neurology & Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, USA
2 shared publications
Latest Publications
- Open Access
Development, Cognitive Interview Testing, and Content Validation of the PERCH-BC Survey for Perceived Weight-Related Effects of Hormonal Contraception
Concerns about weight gain may influence hormonal contraception selection, satisfaction, and discontinuation, yet no validated patient-centered instrument assesses perceived weight-related effects across methods. We developed the Perceived Changes with Hormonal Birth Control (PERCH-BC) survey using sequential face-validity and content-validity phases. Initial items were informed by the literature, questionnaires, and expertise. Fifteen premenopausal women aged 20–45 years—purposively sampled across normal-weight, overweight, and obesity categories—evaluated Versions 1–3 over three rounds of cognitive interviews. Participants completed the survey before retrospective probing focused on comprehension, interpretation, response processes, response-option fit, format, and usability. Interviews were audio-recorded, transcribed, and qualitatively coded; round-specific findings informed sequential revisions. Participants found the survey understandable and acceptable. However, limited contraceptive-method familiarity, difficulty responding under uncertainty, and interpretation of items as factual knowledge questions reduced response confidence. Revisions included a contraceptive-method visual aid, uncertainty response options, belief- and experience-focused instructions, revised wording, and side-effect items. The resulting 25-item Version 4 underwent structured content review by eight interdisciplinary experts evaluating 27 prompts for relevance, clarity, and completeness. All prompts met the prespecified relevance threshold (item-level content validity index [I-CVI], 0.875–1.00); the scale-level average content validity index (S-CVI/Ave) was 0.98. Expert feedback informed minor refinements before subsequent quantitative psychometric validation.
Open AccessDevelopment, Cognitive Interview Testing, and Content Validation of the PERCH-BC Survey for Perceived Weight-Related Effects of Hormonal Contraception
Concerns about weight gain may influence hormonal contraception selection, satisfaction, and discontinuation, yet no validated patient-centered instrument assesses perceived weight-related effects across methods. We developed the Perceived Changes with Hormonal Birth Control (PERCH-BC) survey using sequential face-validity and content-validity phases. Initial items were informed by the literature, questionnaires, and expertise. Fifteen premenopausal women aged 20–45 years—purposively sampled across normal-weight, overweight, and obesity categories—evaluated Versions 1–3 over three rounds of cognitive interviews. Participants completed the survey before retrospective probing focused on comprehension, interpretation, response processes, response-option fit, format, and usability. Interviews were audio-recorded, transcribed, and qualitatively coded; round-specific findings informed sequential revisions. Participants found the survey understandable and acceptable. However, limited contraceptive-method familiarity, difficulty responding under uncertainty, and interpretation of items as factual knowledge questions reduced response confidence. Revisions included a contraceptive-method visual aid, uncertainty response options, belief- and experience-focused instructions, revised wording, and side-effect items. The resulting 25-item Version 4 underwent structured content review by eight interdisciplinary experts evaluating 27 prompts for relevance, clarity, and completeness. All prompts met the prespecified relevance threshold (item-level content validity index [I-CVI], 0.875–1.00); the scale-level average content validity index (S-CVI/Ave) was 0.98. Expert feedback informed minor refinements before subsequent quantitative psychometric validation.
- 21 August 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (9) , 882
Effects of aromatherapy on chemotherapy-related symptom management
Purpose Aromatherapy holds promise for reducing chemotherapy-related symptoms, however, lacks robust clinical evidence. This study evaluates the feasibility and benefit of aromatherapy in managing chemotherapy-related symptoms. Methods This four-arm, randomized, blinded clinical trial enrolled 91 cancer patients (≥ 8 years) undergoing chemotherapy for cancer. Participants were randomized into one of four arms (lavender, jojoba, orange, and ginger) for two chemotherapy cycles (Baseline—no aromatherapy and Cycle 2 – aromatherapy) with an optional third cycle. Participants used aromatherapy inhalers at least 4 times/day for 7 days and rated severity of 7 symptoms (i.e., nausea, vomiting, pain, anxiety, fatigue, sleep difficulties, and lack of appetite) from 0 to 10 daily during each cycle. Primary outcome was feasibility (i.e., retention and aromatherapy compliance through Cycle 2). Preliminary efficacy was evaluated using mean composite symptom severity scores (CSSS; sum daily scores of all individual symptoms for the seven days per cycle). Results Of the 91 participants randomized, 84 participants started Baseline with 68 completing through Cycle 2. Aromatherapy demonstrated feasibility with overall retention rate of 81.0% (68/84) and high acceptability with 83.3% of all participants reporting use of their inhaler ≥ 21 times during Cycle 2, exceeding our targeted ≥ 75% threshold. The overall change in mean CSSS between Cycle 2 and baseline was on average -1.38 (SE = 0.54), showing reduced symptom severity with aromatherapy. Conclusion Aromatherapy is a feasible and acceptable non-pharmacologic integrative modality for chemotherapy symptom management. Further research is needed to validate these findings and explore the underlying mechanisms of aromatherapy’s effects.
- 21 August 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (9) , 882
Effects of aromatherapy on chemotherapy-related symptom management
Purpose Aromatherapy holds promise for reducing chemotherapy-related symptoms, however, lacks robust clinical evidence. This study evaluates the feasibility and benefit of aromatherapy in managing chemotherapy-related symptoms. Methods This four-arm, randomized, blinded clinical trial enrolled 91 cancer patients (≥ 8 years) undergoing chemotherapy for cancer. Participants were randomized into one of four arms (lavender, jojoba, orange, and ginger) for two chemotherapy cycles (Baseline—no aromatherapy and Cycle 2 – aromatherapy) with an optional third cycle. Participants used aromatherapy inhalers at least 4 times/day for 7 days and rated severity of 7 symptoms (i.e., nausea, vomiting, pain, anxiety, fatigue, sleep difficulties, and lack of appetite) from 0 to 10 daily during each cycle. Primary outcome was feasibility (i.e., retention and aromatherapy compliance through Cycle 2). Preliminary efficacy was evaluated using mean composite symptom severity scores (CSSS; sum daily scores of all individual symptoms for the seven days per cycle). Results Of the 91 participants randomized, 84 participants started Baseline with 68 completing through Cycle 2. Aromatherapy demonstrated feasibility with overall retention rate of 81.0% (68/84) and high acceptability with 83.3% of all participants reporting use of their inhaler ≥ 21 times during Cycle 2, exceeding our targeted ≥ 75% threshold. The overall change in mean CSSS between Cycle 2 and baseline was on average -1.38 (SE = 0.54), showing reduced symptom severity with aromatherapy. Conclusion Aromatherapy is a feasible and acceptable non-pharmacologic integrative modality for chemotherapy symptom management. Further research is needed to validate these findings and explore the underlying mechanisms of aromatherapy’s effects.
- Open Access
Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9
In cancer cells, septins assemble into enigmatic higher-order structures of 300-700 nanometers, including long needle-like filaments, thick perinuclear rings, and cytoplasmic bundles or aggregates. The absence of genetic or pharmacological tools to recapitulate these architectures in-vitro has impeded mechanistic studies of their formation, function, and therapeutic targeting. Here, first, determining the overexpression of septin-2 in epithelial ovarian cancer (EOC) and its association with increased mortalities and dependencies, we select SKOV-3 ovarian cancer cells as a tractable model in which septin supramolecular assemblies can be recreated in-vitro and interrogated. This system shows that the forchlorfenuron (FCF) analog UR214-9 remodels septin architecture, converting co-expressed human septin octamers (SEPT2–SEPT6–SEPT7–SEPT9–SEPT9–SEPT7–SEPT6–SEPT2) into large cytoplasmic aggregates. In parallel, transiently expressed SEPT2 is reorganized into septin-rich noodle-like filaments, perinuclear rings, and web-like networks encircling the nucleus upon UR214-9 treatment. Mechanistically, UR214-9 disrupts the incorporation of SEPT2, SEPT7, and SEPT9 into canonical septin hetero-octamers, resulting in assembly-defective or imperfect oligomers that preferentially reorganize into these aberrant higher-order structures. This aggregation likely prevents septin-2 migration during interphase-to-cleavage furrow transition in NRK-49F-SEPT2-EGFP homozygous cells and impacts SKOV-3 cytokinesis, cell proliferation, adhesion and invasion and migration while sparing ceramide transport to the Golgi, preserving ER and cis-Golgi structure. These effects manifested in reduced growth of ovarian, endometrial and breast cancer xenografts without attracting significant off-target engagements per the global transcriptomic analysis of JIMT1 breast cancer and PANC-1 pancreatic cells. UR214-9 treated animals showed observable safety in animals. Thus, a tool to recreate aberrant septin structures and identification of septins as a druggable cytoskeletal target for ovarian, endometrial, breast and pancreatic cancer by perturbing their hetero-octamerization assembly is presented. Significance: We provide a method to reconstruct the higher-order septin architecture observed in cancer cells, to study their assembly and functions. Intriguingly, cancer cells tolerate hetero-oligomeric septins lacking specific subunits, suggesting that compositionally deficient oligomers are not efficiently targeted for degradation, unlike unincorporated septin monomers in normal cells. This tolerance may enable accumulation of structurally aberrant septin complexes acquiring long-needles, rings or thick-aggregates in disease cells. We further show that septin oligomerization can be pharmacologically perturbed. By integrating structural, cellular, and energetic readouts using in-silico techniques, we establish a quantitative framework for septin-targeted modulation, generating UR214-9 as a new chemotype that disrupts septin oligomeric assembly via preventing incorporation of SEPT2/7/9, into canonical hetero-octamers, causes defects in cytokinesis, altered cell migration, viability, and remodels septin–actin architectures, ultimately impairing tumor cell growth. Thus, pharmacological targeting of septin assembly represents a tractable strategy to perturb septin-dependent cellular processes in cancer and neurodegenerative diseases with reported septin dysregulation.
Open AccessReconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9
In cancer cells, septins assemble into enigmatic higher-order structures of 300-700 nanometers, including long needle-like filaments, thick perinuclear rings, and cytoplasmic bundles or aggregates. The absence of genetic or pharmacological tools to recapitulate these architectures in-vitro has impeded mechanistic studies of their formation, function, and therapeutic targeting. Here, first, determining the overexpression of septin-2 in epithelial ovarian cancer (EOC) and its association with increased mortalities and dependencies, we select SKOV-3 ovarian cancer cells as a tractable model in which septin supramolecular assemblies can be recreated in-vitro and interrogated. This system shows that the forchlorfenuron (FCF) analog UR214-9 remodels septin architecture, converting co-expressed human septin octamers (SEPT2–SEPT6–SEPT7–SEPT9–SEPT9–SEPT7–SEPT6–SEPT2) into large cytoplasmic aggregates. In parallel, transiently expressed SEPT2 is reorganized into septin-rich noodle-like filaments, perinuclear rings, and web-like networks encircling the nucleus upon UR214-9 treatment. Mechanistically, UR214-9 disrupts the incorporation of SEPT2, SEPT7, and SEPT9 into canonical septin hetero-octamers, resulting in assembly-defective or imperfect oligomers that preferentially reorganize into these aberrant higher-order structures. This aggregation likely prevents septin-2 migration during interphase-to-cleavage furrow transition in NRK-49F-SEPT2-EGFP homozygous cells and impacts SKOV-3 cytokinesis, cell proliferation, adhesion and invasion and migration while sparing ceramide transport to the Golgi, preserving ER and cis-Golgi structure. These effects manifested in reduced growth of ovarian, endometrial and breast cancer xenografts without attracting significant off-target engagements per the global transcriptomic analysis of JIMT1 breast cancer and PANC-1 pancreatic cells. UR214-9 treated animals showed observable safety in animals. Thus, a tool to recreate aberrant septin structures and identification of septins as a druggable cytoskeletal target for ovarian, endometrial, breast and pancreatic cancer by perturbing their hetero-octamerization assembly is presented. Significance: We provide a method to reconstruct the higher-order septin architecture observed in cancer cells, to study their assembly and functions. Intriguingly, cancer cells tolerate hetero-oligomeric septins lacking specific subunits, suggesting that compositionally deficient oligomers are not efficiently targeted for degradation, unlike unincorporated septin monomers in normal cells. This tolerance may enable accumulation of structurally aberrant septin complexes acquiring long-needles, rings or thick-aggregates in disease cells. We further show that septin oligomerization can be pharmacologically perturbed. By integrating structural, cellular, and energetic readouts using in-silico techniques, we establish a quantitative framework for septin-targeted modulation, generating UR214-9 as a new chemotype that disrupts septin oligomeric assembly via preventing incorporation of SEPT2/7/9, into canonical hetero-octamers, causes defects in cytokinesis, altered cell migration, viability, and remodels septin–actin architectures, ultimately impairing tumor cell growth. Thus, pharmacological targeting of septin assembly represents a tractable strategy to perturb septin-dependent cellular processes in cancer and neurodegenerative diseases with reported septin dysregulation.
- Open Access
- 27 April 2026
- Published by Wiley in Reproductive, Female and Child Health
- Vol. 5 (2)
Revisiting the 4 mm Endometrial Stripe Thickness Threshold for Risk Stratification of Endometrial Cancer
Objective: Type 2 endometrial cancer (EC) histology has been associated with endometrial stripe thickness (EST) < 4 mm, and anatomic factors like obesity, fibroids, and endometrial polyps have been found to impact sonographic interpretation of EST. We aim to evaluate the recommended 4 mm EST threshold for endometrial biopsy in patients with postmenopausal bleeding, with rising incidence of type 2 EC and high prevalence of obesity and uterine structural factors. Methods: This retrospective cohort study identified patients with EC at an academic center (October 2015 to December 2017), abstracting demographic data, EST measurement, presence of fibroids or endometrial polyps, EC histology, grade, and stage at diagnosis. χ 2 tests and logistic regression were performed comparing EST ≤ 4 and > 4 mm groups. Results: 445 patients were included after application of the inclusion/exclusion criteria. Type 1 EC accounted for 83.9% and type 2 for 16.1%. About 8% had EST ≤ 4 mm. Type 2 histology was associated with a higher proportion of EST ≤ 4 mm than type 1 (15.7% vs 6.8%, p = 0.029). Lower BMI was associated with increased odds of EST ≤ 4 mm; OR 5.42 for BMI < 25 versus BMI ≥ 40 kg/m 2 (95% CI 1.29‐22.90, p = 0.021). There was no association of fibroids or polyps with EST. Conclusions: Type 2 EC and lower BMI were associated with EST ≤ 4 mm. The 4 mm EST threshold does not consider cancer histology or factors that impact sonographic interpretation; this threshold should be re‐evaluated, as the current guidelines may put some patients at risk of delayed diagnosis.
- 27 April 2026
- Published by Wiley in Reproductive, Female and Child Health
- Vol. 5 (2)
Open AccessRevisiting the 4 mm Endometrial Stripe Thickness Threshold for Risk Stratification of Endometrial Cancer
Objective: Type 2 endometrial cancer (EC) histology has been associated with endometrial stripe thickness (EST) < 4 mm, and anatomic factors like obesity, fibroids, and endometrial polyps have been found to impact sonographic interpretation of EST. We aim to evaluate the recommended 4 mm EST threshold for endometrial biopsy in patients with postmenopausal bleeding, with rising incidence of type 2 EC and high prevalence of obesity and uterine structural factors. Methods: This retrospective cohort study identified patients with EC at an academic center (October 2015 to December 2017), abstracting demographic data, EST measurement, presence of fibroids or endometrial polyps, EC histology, grade, and stage at diagnosis. χ 2 tests and logistic regression were performed comparing EST ≤ 4 and > 4 mm groups. Results: 445 patients were included after application of the inclusion/exclusion criteria. Type 1 EC accounted for 83.9% and type 2 for 16.1%. About 8% had EST ≤ 4 mm. Type 2 histology was associated with a higher proportion of EST ≤ 4 mm than type 1 (15.7% vs 6.8%, p = 0.029). Lower BMI was associated with increased odds of EST ≤ 4 mm; OR 5.42 for BMI < 25 versus BMI ≥ 40 kg/m 2 (95% CI 1.29‐22.90, p = 0.021). There was no association of fibroids or polyps with EST. Conclusions: Type 2 EC and lower BMI were associated with EST ≤ 4 mm. The 4 mm EST threshold does not consider cancer histology or factors that impact sonographic interpretation; this threshold should be re‐evaluated, as the current guidelines may put some patients at risk of delayed diagnosis.
- 27 April 2026
- Published by SAGE Publications in Population Health Management
- Vol. 29 (5) , 297-302
The Impact of Social Vulnerability and Race on Colorectal Cancer Screening
Colorectal cancer (CRC) is a leading contributor to morbidity and mortality in the United States, with documented disparities in screening rates across racial lines. This study examined the intersection of race and social vulnerability in CRC screening rates. We examined 117,424 patients eligible for CRC screening in New York State. We assessed CRC screening among individuals aged 45–80 based on Healthcare Effectiveness Data and Information Set guidelines. We used Social Vulnerability Indices (SVIs) geocoded to each patient’s census track. We employed log-binomial multivariate regression models with interaction terms to evaluate the effects of race and social vulnerability on CRC screening rates, while controlling for age, sex, marital status, and community type. Among 117,424 patients eligible for CRC screening, 75.2% of patients ( n = 88,276) were effectively screened. Screening rates varied based on race (White 76.2%; Black 64.4%; P < 0.0001). CRC screening rates declined with increasing social vulnerability among both Black and White patients. Among patients in the most socially vulnerable groups, the adjusted rate of screening was 3.8%–8.4% lower for Black patients compared to White patients. In contrast, within the least socially vulnerable (most affluent) group, there was no statistical difference in the rate of CRC screening by race (adjusted risk ratio = 0.981; P = 0.201). The impact of social vulnerability was experienced disproportionately by Black patients. Among patients living in the most vulnerable census tracts, Black patients were significantly less likely to be screened for CRC compared to White patients facing similar social vulnerability. In contrast, we did not observe a difference in screening rates by race in the most affluent (least socially vulnerable) group.
- 27 April 2026
- Published by SAGE Publications in Population Health Management
- Vol. 29 (5) , 297-302
The Impact of Social Vulnerability and Race on Colorectal Cancer Screening
Colorectal cancer (CRC) is a leading contributor to morbidity and mortality in the United States, with documented disparities in screening rates across racial lines. This study examined the intersection of race and social vulnerability in CRC screening rates. We examined 117,424 patients eligible for CRC screening in New York State. We assessed CRC screening among individuals aged 45–80 based on Healthcare Effectiveness Data and Information Set guidelines. We used Social Vulnerability Indices (SVIs) geocoded to each patient’s census track. We employed log-binomial multivariate regression models with interaction terms to evaluate the effects of race and social vulnerability on CRC screening rates, while controlling for age, sex, marital status, and community type. Among 117,424 patients eligible for CRC screening, 75.2% of patients ( n = 88,276) were effectively screened. Screening rates varied based on race (White 76.2%; Black 64.4%; P < 0.0001). CRC screening rates declined with increasing social vulnerability among both Black and White patients. Among patients in the most socially vulnerable groups, the adjusted rate of screening was 3.8%–8.4% lower for Black patients compared to White patients. In contrast, within the least socially vulnerable (most affluent) group, there was no statistical difference in the rate of CRC screening by race (adjusted risk ratio = 0.981; P = 0.201). The impact of social vulnerability was experienced disproportionately by Black patients. Among patients living in the most vulnerable census tracts, Black patients were significantly less likely to be screened for CRC compared to White patients facing similar social vulnerability. In contrast, we did not observe a difference in screening rates by race in the most affluent (least socially vulnerable) group.
- Open Access
Current Body Mass Index Is Associated with Reported Weight Gain as a Reason for Discontinuing Oral Contraceptive Pill Use
Concerns about weight gain are commonly cited with combined oral contraceptive pill (COCP) use, yet it remains unclear whether perceived weight gain as a reason for discontinuation differs by body mass index (BMI). We analyzed data from the 2017–2019 National Survey of Family Growth (NSFG), including 3709 non-pregnant women aged 20–49 years who had ever used COCPs and had BMI calculated from self-reported height and weight. Trained NSFG staff interviewed participants on reasons for discontinuation and coded them into predefined categories, including weight gain. Discontinuation was examined by BMI category (underweight, normal weight, overweight, obesity) using survey-weighted logistic regression adjusted for demographic and socioeconomic covariates. Overall, 35.2% (95% CI 32.3–38.1%) of women reported discontinuing COCPs due to dissatisfaction, with 20.2% (95% CI 18.1–22.3%) citing side effects. Weight gain was reported by 7.0% (95% CI 5.6–8.4%) of ever-users, with higher prevalence among women with overweight (8.4%) and obesity (7.7%) compared with normal-weight women (5.5%). In adjusted analyses, women with overweight (aOR 1.76, p = 0.048) and obesity (aOR 1.68, p = 0.033) had higher odds of COCP discontinuation due to self-reported weight gain. These findings highlight the importance of addressing weight-related concerns during contraceptive counseling, particularly for women with higher BMI.
Open AccessCurrent Body Mass Index Is Associated with Reported Weight Gain as a Reason for Discontinuing Oral Contraceptive Pill Use
Concerns about weight gain are commonly cited with combined oral contraceptive pill (COCP) use, yet it remains unclear whether perceived weight gain as a reason for discontinuation differs by body mass index (BMI). We analyzed data from the 2017–2019 National Survey of Family Growth (NSFG), including 3709 non-pregnant women aged 20–49 years who had ever used COCPs and had BMI calculated from self-reported height and weight. Trained NSFG staff interviewed participants on reasons for discontinuation and coded them into predefined categories, including weight gain. Discontinuation was examined by BMI category (underweight, normal weight, overweight, obesity) using survey-weighted logistic regression adjusted for demographic and socioeconomic covariates. Overall, 35.2% (95% CI 32.3–38.1%) of women reported discontinuing COCPs due to dissatisfaction, with 20.2% (95% CI 18.1–22.3%) citing side effects. Weight gain was reported by 7.0% (95% CI 5.6–8.4%) of ever-users, with higher prevalence among women with overweight (8.4%) and obesity (7.7%) compared with normal-weight women (5.5%). In adjusted analyses, women with overweight (aOR 1.76, p = 0.048) and obesity (aOR 1.68, p = 0.033) had higher odds of COCP discontinuation due to self-reported weight gain. These findings highlight the importance of addressing weight-related concerns during contraceptive counseling, particularly for women with higher BMI.
- Open Access
A Pilot and Feasibility Study of Combined Oral Contraceptive Pills and Metabolic Outcomes in Premenopausal Women with Overweight or Obesity
Combined oral contraceptive pills (COCPs) are commonly used by reproductive-aged women with overweight or obesity, but their metabolic effects remain understudied. This pilot study examined the feasibility of recruiting and retaining women with overweight or obesity initiating COCPs and evaluated changes in body weight, body composition, energy intake (EI), eating behaviors, and cardiometabolic markers. Premenopausal women aged 18–40 years with a body mass index between 25 and 45 kg/m2 initiating COCPs (n = 10) or using nonhormonal contraception (NHC; n = 10) were followed for six months. Outcome measures included body weight, body composition, EI, eating behavior questionnaires, ecological momentary assessment of appetite and satiety, and fasting laboratory measures. There were no between-group differences in changes in weight, EI, or appetite. Binge-eating severity decreased in COCP users and increased in NHC users, though the within-group change in COCP users was not statistically significant. Exploratory analyses demonstrated increases in hemoglobin A1c and triglycerides among COCP users compared to NHC users, while bioavailable testosterone decreased in COCP users only. This study demonstrates high retention and feasibility among women with overweight/obesity undergoing intensive dietary and metabolic monitoring. Although weight outcomes were similar between groups, these preliminary findings identify potential metabolic signals warranting confirmation in adequately powered studies.
Open AccessA Pilot and Feasibility Study of Combined Oral Contraceptive Pills and Metabolic Outcomes in Premenopausal Women with Overweight or Obesity
Combined oral contraceptive pills (COCPs) are commonly used by reproductive-aged women with overweight or obesity, but their metabolic effects remain understudied. This pilot study examined the feasibility of recruiting and retaining women with overweight or obesity initiating COCPs and evaluated changes in body weight, body composition, energy intake (EI), eating behaviors, and cardiometabolic markers. Premenopausal women aged 18–40 years with a body mass index between 25 and 45 kg/m2 initiating COCPs (n = 10) or using nonhormonal contraception (NHC; n = 10) were followed for six months. Outcome measures included body weight, body composition, EI, eating behavior questionnaires, ecological momentary assessment of appetite and satiety, and fasting laboratory measures. There were no between-group differences in changes in weight, EI, or appetite. Binge-eating severity decreased in COCP users and increased in NHC users, though the within-group change in COCP users was not statistically significant. Exploratory analyses demonstrated increases in hemoglobin A1c and triglycerides among COCP users compared to NHC users, while bioavailable testosterone decreased in COCP users only. This study demonstrates high retention and feasibility among women with overweight/obesity undergoing intensive dietary and metabolic monitoring. Although weight outcomes were similar between groups, these preliminary findings identify potential metabolic signals warranting confirmation in adequately powered studies.
- Open Access
- 7 March 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (2) , 1-5
Results of Lung Cancer Screening at a Rural hospital network in the United States.
Introduction and Background: Lung cancer is second most common cancer in the world. USPSTF has specific guidelines for lung cancer screening in high-risk individuals. Multiple studies including NLST trail has shown reduction in lung cancer mortality with lung cancer screening. Most of these studies focus in the urban population and there are very few studies that have studied lung cancer screening in rural US population. Materials and methods: This is a retrospective study reviewing patients that were diagnosed with lung cancer after undergoing lung cancer screening in a rural hospital network. Results: In our study, lung cancer detection rate was 2.96% (74 cases out of 2500 cases screened) .63.3% of cancer patients were diagnosed in stage I. The median household income was $50,262 which was below the average median household income for United States. The median pack years of the cancer patients was 50 pack years. Significant proportion of cancer patients were referred by either Nurse Practitioners or Physician Assistants (43%) compared to physicians (57%) . Conclusion: LDCT scan can play a pivotal role in detection of lung cancer at early stages in rural population.
- 7 March 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (2) , 1-5
Open AccessResults of Lung Cancer Screening at a Rural hospital network in the United States.
Introduction and Background: Lung cancer is second most common cancer in the world. USPSTF has specific guidelines for lung cancer screening in high-risk individuals. Multiple studies including NLST trail has shown reduction in lung cancer mortality with lung cancer screening. Most of these studies focus in the urban population and there are very few studies that have studied lung cancer screening in rural US population. Materials and methods: This is a retrospective study reviewing patients that were diagnosed with lung cancer after undergoing lung cancer screening in a rural hospital network. Results: In our study, lung cancer detection rate was 2.96% (74 cases out of 2500 cases screened) .63.3% of cancer patients were diagnosed in stage I. The median household income was $50,262 which was below the average median household income for United States. The median pack years of the cancer patients was 50 pack years. Significant proportion of cancer patients were referred by either Nurse Practitioners or Physician Assistants (43%) compared to physicians (57%) . Conclusion: LDCT scan can play a pivotal role in detection of lung cancer at early stages in rural population.
- Open Access
- 2 August 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-9
Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)
The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institution retrospective study included BCBM patients who have received stereotactic radiosurgery (SRS) to brain. Separate endpoints [CNS failure-free survival (cFFS), overall survival (OS)] were analyzed from each Landmark (LM): LM1 (3-months), LM2 (6-months). Patients were categorized into early and non-early progression (EP, NEP) groups depending on SD status before LMs. Median survivals from LM were assessed with Kaplan Meier plots, compared with Log-Rank test. EP was associated with worse median cFFS and OS vs NEP in both LM analyses (cFFS- LM1: 3.6 vs. 9.7 months, p = 0.0016; LM2: 2.3 vs. 12.5 months, p < 0.0001; OS- LM1: 3.6 vs. 24.3 months, p < 0.0001; LM2: 5.3 vs. 30.2 months, p < 0.0001). In multivariate analyses, EP was associated with shorter cFFS [LM1: Hazard Ratio (HR) with 95% confidence interval (CI) 3.16, 1.46–6.83, p = 0.0034; LM2: 5.32, 2.33–12.15, p = p = 0.0002; LM2: 7.40, 3.10–17.63, p = <0.0001) vs NEP. Early systemic disease progressions after 1st SRS to brain is associated with worse cFFS and OS in patients with BCBM.
- 2 August 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-9
Open AccessImpact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)
The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institution retrospective study included BCBM patients who have received stereotactic radiosurgery (SRS) to brain. Separate endpoints [CNS failure-free survival (cFFS), overall survival (OS)] were analyzed from each Landmark (LM): LM1 (3-months), LM2 (6-months). Patients were categorized into early and non-early progression (EP, NEP) groups depending on SD status before LMs. Median survivals from LM were assessed with Kaplan Meier plots, compared with Log-Rank test. EP was associated with worse median cFFS and OS vs NEP in both LM analyses (cFFS- LM1: 3.6 vs. 9.7 months, p = 0.0016; LM2: 2.3 vs. 12.5 months, p < 0.0001; OS- LM1: 3.6 vs. 24.3 months, p < 0.0001; LM2: 5.3 vs. 30.2 months, p < 0.0001). In multivariate analyses, EP was associated with shorter cFFS [LM1: Hazard Ratio (HR) with 95% confidence interval (CI) 3.16, 1.46–6.83, p = 0.0034; LM2: 5.32, 2.33–12.15, p = p = 0.0002; LM2: 7.40, 3.10–17.63, p = <0.0001) vs NEP. Early systemic disease progressions after 1st SRS to brain is associated with worse cFFS and OS in patients with BCBM.
- Open Access
Forchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer
Forchlorfenuron (FCF) is a widely used plant cytokinin that enhances fruit quality and size in agriculture. It also serves as a crucial pharmacological tool for the inhibition of septins. However, the precise target of FCF has not yet been fully determined. This study reveals a novel target of FCF and elucidates its downstream signaling events. FCF significantly impairs mitochondrial respiration and mediates metabolic shift toward glycolysis, thus making cells more vulnerable to glycolysis inhibition. Interestingly, FCF’s impact on mitochondrial function persists, even in cells lacking septins. Furthermore, the impaired mitochondrial function leads to the degradation of HIF-1α, facilitated by increased cellular oxygen. FCF also induces AMPK activation, suppresses Erk1/2 phosphorylation, and reduces the expression of HER2, β-catenin, and PD-L1. Endometrial cancer is characterized by metabolic disorders such as diabetes and aberrant HER2/Ras-Erk1/2/β-catenin signaling. Thus, FCF may hold promise as a potential therapeutic in endometrial cancer.
Open AccessForchlorfenuron-Induced Mitochondrial Respiration Inhibition and Metabolic Shifts in Endometrial Cancer
Forchlorfenuron (FCF) is a widely used plant cytokinin that enhances fruit quality and size in agriculture. It also serves as a crucial pharmacological tool for the inhibition of septins. However, the precise target of FCF has not yet been fully determined. This study reveals a novel target of FCF and elucidates its downstream signaling events. FCF significantly impairs mitochondrial respiration and mediates metabolic shift toward glycolysis, thus making cells more vulnerable to glycolysis inhibition. Interestingly, FCF’s impact on mitochondrial function persists, even in cells lacking septins. Furthermore, the impaired mitochondrial function leads to the degradation of HIF-1α, facilitated by increased cellular oxygen. FCF also induces AMPK activation, suppresses Erk1/2 phosphorylation, and reduces the expression of HER2, β-catenin, and PD-L1. Endometrial cancer is characterized by metabolic disorders such as diabetes and aberrant HER2/Ras-Erk1/2/β-catenin signaling. Thus, FCF may hold promise as a potential therapeutic in endometrial cancer.